FOLFIRINOX May Have Longer Median OS Than Gemcitabine for Pancreatic Cancer

Share this content:
First-line FOLFIRINOX treatment appears to result in a higher overall survival in patients with advanced pancreatic cancer.
First-line FOLFIRINOX treatment appears to result in a higher overall survival in patients with advanced pancreatic cancer.

First-line fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) resulted in a median overall survival of 24.2 months in patients with locally advanced pancreatic cancer, longer than the 6 to 13 months reported with gemcitabine, a meta-analysis published in the journal The Lancet Oncology has shown.1

Because several studies have investigated the efficacy of systemic chemotherapy with FOLFIRINOX in patients with locally advanced pancreatic cancer, researchers sought to conduct a systematic review of the FOLFIRINOX studies to evaluate its effectiveness as frontline therapy in this patient population.

For the study, researchers analyzed data from 315 patients with locally advanced disease who received first-line FOLFIRINOX in 11 studies. Results showed that median overall survival from the initiation of chemotherapy ranged from 10.0 months (95% CI, 4.0-16.0) to 32.7 months (95% CI, 23.1-42.3) across the 11 studies. The pooled patient-level median overall survival was 24.2 months (95% CI, 21.7-26.8).

Researchers found that median progression-free survival ranged from 3.0 months (95% CI, not calculable) to 20.4 months (95% CI, 6.5-34.3) across the studies. Patient-level median progression-free survival was 15.0 months (95% CI, 13.8-16.2).

In terms of safety, 296 grade 3 or 4 adverse events among 490 patients from 10 studies. No deaths were related to FOLFIRINOX therapy.

The study further demonstrated that 57% of 271 patients from 8 studies received radiotherapy or chemoradiotherapy after FOLFIRINOX treatment. A total of 63.5% (95% CI, 43.3-81.6) of patients received radiation treatment and 25.9% (95% CI, 20.2-31.9) underwent resection after FOLFIRINOX. The pooled proportion of patients who had R0 resection was 78.4% (95% CI, 60.2-92.2).

RELATED: Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

These promising findings ultimately suggest that they should be further evaluated in a randomized controlled trial, and future research should determine which patients might benefit from radiotherapy, chemoradiotherapy, or resection following FOLFIRINOX treatment.

Reference

  1. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis [published online ahead of print May 6, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(16)00172-8.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs